بدائل البحث:
means decrease » mean decrease (توسيع البحث), deaths decreased (توسيع البحث)
large decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث), large increases (توسيع البحث)
step decrease » sizes decrease (توسيع البحث), teer decrease (توسيع البحث), we decrease (توسيع البحث)
i means » _ means (توسيع البحث), k means (توسيع البحث)
means decrease » mean decrease (توسيع البحث), deaths decreased (توسيع البحث)
large decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث), large increases (توسيع البحث)
step decrease » sizes decrease (توسيع البحث), teer decrease (توسيع البحث), we decrease (توسيع البحث)
i means » _ means (توسيع البحث), k means (توسيع البحث)
-
1
-
2
-
3
-
4
ECoG timescales decrease during spatial attention.
منشور في 2025"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"
-
5
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
منشور في 2025"…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …"
-
6
-
7
-
8
-
9
Loss of Vps34 is associated with decreased eTreg survival but intact activation.
منشور في 2025الموضوعات: -
10
-
11
-
12
-
13
-
14
-
15
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
منشور في 2025الموضوعات: -
16
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
منشور في 2025"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …"
-
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
19
-
20